Vimarsana
Biggest News Aggregation in the World

Page 3 - Jack Spinks News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Jack Spinks. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Jack Spinks Today - Breaking & Trending Today

Zymeworks Reports Fourth Quarter and Full Year 2022 Financial Results - Vimarsana News

Zymeworks Reports Fourth Quarter and Full Year 2022 Financial Results

2022 was a year of transformation and change:reported $412.5 million in total revenue for the year ended December 31, 2022;reported net income of $124.3 million ($1.90 per fully diluted share) for 2022 compared to net loss of $211.8 million in 2021;reported $492.2 million in cash resources as of December 31, 2022, w...

Zymeworks To Host Fourth Quarter And Full Year 2022 Results Conference Call - Vimarsana News

Zymeworks To Host Fourth Quarter And Full Year 2022 Results Conference Call

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will report its fourth quarter and full year 2022 financial results after market close on March 7th, 2023. Following t...

Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma - Vimarsana News

Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma

Results presented today at ASCO GI include first overall survival (OS) data for zanidatamab, overall confirmed objective response rate (cORR) of 79%, disease...

Jazz Pharmaceuticals plc: Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma - Vimarsana News

Jazz Pharmaceuticals plc: Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma

Results presented today at ASCO GI include first overall survival (OS) data for zanidatamab, overall confirmed objective response rate (cORR) of 79%, disease control rate (DCR) of

Zymeworks Inc. (NYSE:ZYME) Q3 2022 Earnings Call Transcript - Vimarsana News

Zymeworks Inc. (NYSE:ZYME) Q3 2022 Earnings Call Transcript

Operator: Ladies and gentlemen, thank you for standing by. This is conference operator. Welcome to Zymeworks Third Quarter 2022 Results Conference Call and Webcast.